混合Ti (IV) -Chrysin系统的结构规范-生物分析和抗菌,抗炎和组织特异性抗癌活性
Sevasti Matsia1, Georgios Lazopoulos1, Antonios Hatzidimitriou2
1Laboratory of Inorganic Chemistry and Advanced Materials, School of Chemical Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Molecules (Basel, Switzerland)
|September 27, 2025
概括
新的金金属有机化合物显示出作为抗菌和抗炎剂的前景. 这些新型金属药物表现出对抗细菌和炎症的增强活性,具有未来治疗应用的潜力.
科学领域:
- 协调化学 协调化学
- 材料科学 材料科学 材料科学
- 药用化学 医学化学
背景情况:
- 含有黄和金属离子的金属有机化合物对生物应用很有兴趣.
- (IV) 和 (Chr) 形成了独特的单核和四核组件.
研究的目的:
- 为了合成和表征新的-化金属-有机化合物.
- 研究它们的化学反应性,结构性质和生物活动.
- 为潜在的金属药物开发建立结构-活动关系.
主要方法:
- 合成二进制 (Ti ((IV) -Chr) 和三进制 (Ti ((IV) -Chr-phen) 复合物.
- 使用元素分析,光谱学 (FT-IR,UV-Vis,NMR,ESI-MS),晶体学和发光的物理化学表征.
- 理论分析包括Hirshfeld和BVS计算.
- 在体外评估抗菌,抗炎 (BSA变性) 和细胞毒性试验.
主要成果:
- 合成和表征了独特的单核和四核Ti (IV) -Chr结构.
- 与自由合物/金属相比,这些化合物对大肠杆菌和金黄色杆菌具有增强的抗菌活性.
- 观察到显著的抗炎性质,超过了克瑞辛和迪克洛芬雅克.
- 在体外研究显示了癌症和正常细胞系中的结构-组织反应概况.
结论:
- 新型-金金属有机化合物具有显著的抗菌和抗炎作用.
- 结构特征与观察到的生物活动相关.
- 这些发现支持将这些化合物发展为未来的金属药物.
相关概念视频
01:19Phase II Reactions: Miscellaneous Conjugation Reactions
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...